At a glance
ClinicalIndex Comparison RecordN/ACompleted· 327,624 enrolled
Drug / intervention
Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-country Non-interventional Study on the Effectiveness of Empagliflozin in Adult Patients With Type 2 Diabetes in Europe and Asia.
In Brief
An observational study evaluating Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor and Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor for Diabetes Mellitus, Type 2. Completed, enrolled 327,624 participants across 13 sites in 11 countries.
Detailed Summary
Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesDenmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartApr 2019
Primary CompletionDec 2021
TodayJul 2026
First PostedJan 25, 2019
Enrollment StartApr 15, 2019
Primary CompletionDec 10, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.4 years ago
Interventions
Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitordrug
Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitordrug
Dipeptidyl peptidase-4 (DPP-4) inhibitor